Novelos Therapeutics, Inc.

NEWTON, MA 02458

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $2.44MM
First Award Date 09/22/07
Most Recent Award Date 09/30/15

Key Personnel

Last Name Name Awards Contact
Tew Kenneth D. Tew 1
TITZ BENJAMIN TITZ 2

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/15 - 07/29/18

Poor prognosis of triple negative breast cancer (TNBC) is attributable to the absence of efficacious, molecularly-targeted, neoadjuvant therapies. Micrometastases contribute to poor prognosis by increasing recurrence rate. Consequently, an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/15 - 06/29/16

Poor prognosis of triple negative breast cancer (TNBC) is attributable to the absence of efficacious, molecularly-targeted, neoadjuvant therapies. Micrometastases contribute to poor prognosis by increasing recurrence rate. Consequently, an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 09/22/07 - 08/31/09

DESCRIPTION (provided by applicant): The goal of this A2 revised Phase I STTR is to combine the expertise of an academic team with the resources of Novelos Therapeutics Inc. to study a new injectable small molecule derivative of a proprietary and stabilized formulation of oxidized glutathione (GSSG) called NOV-002. Existing clinical results from...